

## Freedom of Information Request: Our Reference CTMUHB\_266\_25

### You asked:

I have a freedom of information request.

### A. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aquipta) – any disease**
- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepti) – any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Rimegepant (Vydura) – any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

Please find below tables populated with the data that Medicines Management are able to provide in relation to your enquiry.

The data provided for Secondary Care relates to the latest 4 months available which is 1st February 2025 to 30<sup>th</sup> June 2025.

Unfortunately, we are unable to provide Botulinum Toxin data by patient numbers because not all the issues are made to individuals. Therefore, we have provided Botulinum Toxin information by number of issues.

The data provided for Primary Care relates the latest 4 months available which is 1<sup>st</sup> December 24 to 31<sup>st</sup> March 2025. Unfortunately, we are unable to provide this data by number of patients due to the way the information is recorded in the electronic systems.

### Secondary Care

Medicine	Number of Patients
Atogepant (Aquipta) – any disease	21
Erenumab (Aimovig) - any disease	10
Eptinezumab (Vyepti) – any disease	0
Fremanezumab (Ajovy) - any disease	41

Galcanezumab (Emgality) - any disease	23
Rimegepant (Vydura) - any disease	24

**Secondary Care**

Medicine	Number of Issues
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - For any indication	318

**Primary Care**

Medicine	Items - Base Period
Rimegepant Oral Lyophilisates Sugar Free	56

**B. How many patients have you treated in the last 4 months for acute migraine with:**

- **Rimegepant (Vydura)**

Data on issue by indication (acute migraine) is not centrally recorded. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

**C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?**

A treatment pause is routinely and actively considered at 12 months, but the decision to actually discontinue is made on a case-by-case basis and not necessarily mandated, depending upon patient characteristics.